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Assessing the prevalence of HIV, HBV, and HCV infection 
among people with severe mental illness 
People with severe mental illness are at higher risk for HIV 
infection than the general population. Early studies in 
New York1 suggested that the prevalence of HIV infection 
among people with severe mental illness was variable, 
depending on factors such as homelessness, treatment 
setting and status, speciﬁ c psychotic diagnosis, dual 
diagnosis with substance use disorders, and sampling 
method (open vs anonymous). General population risk 
factors for HIV infection also have their expected eﬀ ects 
in people with severe mental illness, including high-risk 
sexual activity (among men who have sex with men, 
heterosexuals, or injection drug users), injection drug use, 
ethnicity, gender, age, and viral load at time of exposure. 
Additional factors directly related to severe mental illness 
are cognitive impairment and psychotic symptoms that 
impede the planned use of precautions for risk in sexual 
activity and injection drug use, which present special 
diﬃ  culties to controlling HIV in this population.2 Thus, 
the eﬃ  cacy of antipsychotic treatment and adherence to 
treatment is relevant to the risk of blood-borne infections 
in people with severe mental illness.
In The Lancet Psychiatry, Elisabeth Hughes and 
colleagues3 make a major contribution to this subject by 
examining the prevalences of HIV, hepatitis C virus, and 
hepatitis B virus infection simultaneously in patients 
with severe mental illness. They used a well-deﬁ ned 
approach to identify relevant articles and to deﬁ ne 
the studies by speciﬁ c conditions of testing (although 
“AIDS” could have been added as a search term and 
AIDSLine as a database). They included people aged 
older than 15 years, diagnosed with severe mental 
illness, and treated in a psychiatric setting. Studies in 
which prevalence data were obtained only from case 
notes, self-report, or the grey literature were excluded. 
They determined the eligibility of studies by a consensus 
strategy and used the Quality Assessment Tool for 
Systematic Reviews of Observational Studies4 to assess 
study quality. Hughes and colleagues3 modiﬁ ed the tool 
to show whether participants were clearly deﬁ ned as 
having severe mental illness (yes or no), participation 
rate (>60%=1, ≤60%=0), whether control variables 
were used (controlled=1, only descriptive=0), and 
sample size (≥200 participants=1, <200 participants=0), 
although the eﬀ ects of these modiﬁ cations on reliability 
and validity are not known. They did a meta-analysis 
to calculate combined estimates and 95% CIs for each 
continent. Logistic regression was done to allow for 
the proportions being unable to have values less than 
0, and random eﬀ ects were assumed because there was 
clear clinical heterogeneity among the samples.
The 373 reports they found included 169 (45%) 
duplicates and they excluded 41 (11%) because the 
full-text was not available in English and 74 (20%) 
because they were deemed ineligible. With the addition 
of two papers from an updated search, the authors 
had 91 articles for assessment. This reduction might 
limit the generalisability of the ﬁ ndings. HIV infection 
had the largest sample size and was the subject of the 
most studies: 44 studies assessed HIV (21 071 patients), 
19 assessed hepatitis B virus (8163 patients), and 
28 studies assessed hepatitis C virus (14 888 patients). 
Most of the HIV and hepatitis C virus studies were 
from the USA, and few were from Europe, although 
the investigators attempted to control for continent. 
Ultimately, the most important unit for analysis here 
might be number of studies rather than the cumulative 
number of participants across studies.5
Most studies used convenience samples from 
in-patient psychiatric treatment settings; yet, the 
studies show that data from patients who are not in 
treatment are needed to best approximate the entire 
population of patients with severe mental illness.1 It is 
also important to estimate the number of patients with 
severe mental illness who are dually diagnosed with 
substance use disorders to maximise generalisability, 
because blood-borne infections are much more common 
in this group.6 Another issue not addressed by Hughes 
and colleagues3 was the percentage of patients with 
dual and triple co-infections. Hepatitis C virus co-
infection occurs in as many as 25% of patients with HIV 
in the USA.7 Worldwide, 10% of patients with HIV are co-
infected with hepatitis B virus,8 with as many as 20% in 
southeast Asia. The exact number of patients co-infected 
with hepatitis B virus and hepatitis C virus is unknown; 
an estimated 9–30% of patients with chronic hepatitis 
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Finally, triple infection has been reported in less than 1% 
of residents in Nairobi, Kenya,10 and in as many as 12% 
of patients with HIV infection in central China.11 Hence, 
assessing the proportion of patients with severe mental 
illness who have these co-infections would be of interest. 
For patients with HIV, a report of their CD4 cell count 
and Centers for Disease Control and Prevention clinical 
disease stage at the time of infection would be useful 
to gauge the chronicity of infection and relate it to the 
psychiatric and trauma history of these patients. The 
distribution of HIV risk factors in this subgroup would 
also be worthy of examination.
Hughes and colleagues3 state that although 30–50% of 
patients with severe mental illness have substance use 
disorders, intravenous drug use in this population is rare. 
Yet, the primary route of transmission of hepatitis B virus 
and hepatitis C virus is by intravenous drug use (globally 
roughly 90% for hepatitis C virus), and intravenous drug 
use is a lesser but signiﬁ cant risk for HIV infection. More 
than 25% of homeless people with severe mental illness 
in one study reported the use of intravenous drugs at 
some time in their lives,12 which is probably generally 
representative of the USA. Another factor that bears 
on estimates of the prevalence of these viral infections 
in people with severe mental illness is the percentage 
of homeless patients included in these studies. 
Although all the studies included patients characterised 
as having severe mental illness, the proportions of 
speciﬁ c psychotic diagnoses in each sample varied, 
and the method of ensuring that patients had severe 
mental illness rather than simply being psychiatric in-
patients was not presented. Furthermore, although the 
sensitivity analyses showed no eﬀ ect of study quality 
on these prevalences, the lack of such an eﬀ ect does not 
prove that study quality is irrelevant.
In conclusion, Hughes and colleagues’ focus on the 
concomitant estimations of prevalence of HIV, hepatitis 
B virus, and hepatitis C virus infections in people 
with severe mental illness is an important ﬁ rst eﬀ ort 
to examine the broader issue of this group’s medical 
susceptibility. Future studies should examine the 
prevalence of co-infections of these three viruses, the 
relations between risk factors and contracting infection 
as well as the necessary controls needed in analyses 
for each of these infections. The generalisability of the 
risk factor distributions reported should be assessed 
separately against those of the entire population 
for each infection. A random sampling approach 
would be helpful in future studies of this population. 
Most importantly, it cannot be concluded that only 
typical viral risk factors apply to this population 
when the risk factors speciﬁ c to patients with severe 
mental illness have not been taken into account 
(eg, cognitive impairment and psychotic symptom 
severity). Patients with severe mental illness often 
have chronic cognitive impairment, which can impede 
their adherence to antipsychotic medications, resulting 
in ongoing psychotic symptoms that prevent access 
to and implementation of precautions to prevent 
these infections. Future research should assess the 
contributions of these factors to the additional risk for 
these infections in patients with severe mental illness. 
Health providers in the USA should discuss sexual 
health and risk for blood-borne viral infections with 
patients who have severe mental illness and oﬀ er HIV 
testing to all patients aged 13–64 years at least once 
in their lifetime and oﬀ er hepatitis C virus testing once 
to all adults born between 1945 and 1965 (without 
previous ascertainment of risk factors for hepatitis 
C virus), as per guidelines of the Centers for Disease 
Control and Prevention; screening for hepatitis B virus 
should be oﬀ ered only under speciﬁ c circumstances 
(continuing risk should result in more frequent testing). 
Internationally, WHO sets screening guidelines for HIV, 
hepatitis B virus, and hepatitis C virus.
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Over the past decade the personal, family, societal, 
and global negative eﬀ ects of depression have been 
unequivocally demonstrated.1 Untreated depression 
is a major public health issue that aﬀ ects both mental 
and physical health and many aspects of personal and 
public life, including relationships and educational 
outcomes.  Despite the growing evidence base 
highlighting the need to reach populations at increased 
risk of developing depression and the importance of 
intervening in the adolescent period,2–4 primary care and 
mental health services have remained poorly resourced 
and, therefore, predominantly reactive. The group most 
likely to receive treatment for depression are those 
able to seek services and engage with the treatment 
approaches on oﬀ er. Some subgroups are poorly 
represented, such as children,5 who are dependent on 
adults to identify their needs, advocate for them, and 
enable them to access services. In most high-income 
countries, less than half of the children who need 
mental health services are actually seen;5 these ﬁ gures 
are considerably worse for low-income and middle-
income settings.6 It is therefore essential to address 
why the majority of children do not access services in a 
timely or consistent manner.2  
In The Lancet Psychiatry, Stephan Collishaw and 
colleagues7 present ﬁ ndings from a community sample 
of parents with recurrent depressive episodes studied 
over 4 years. They report on a small subsample of 
oﬀ spring who were more resilient than the others—only 
53 (20%) of 262 study children (mostly adolescents) 
did not experience concerning psychological symptoms 
or had better than expected outcomes. They explore 
the possible explanations for these better outcomes 
and highlight some protective factors. The factors that 
bestow greatest protection include the presence of 
supportive co-parents, good quality social relationships, 
self-eﬃ  cacy, and regular exercise. 
This study highlights the combined role protective 
factors might have for adolescents at risk of depression 
as the oﬀ spring did better with increasing protective 
factors present. Further studies will hopefully 
conduct more detailed multidisciplinary enquiry of 
a greater range of protective factors investigating 
several domains (such as those within families, peer 
groups, schools, communities, and beyond). Multiple 
perspectives, including the voice of the young person, 
can only improve our understanding of the many 
potential inﬂ uences at play. Focusing on protective 
factors adds an important dimension to preventive 
interventions. These ﬁ ndings, alongside other key 
studies, reinforce the importance of thinking about 
family-approaches to identifying and treating 
depression. For example, the data from STAR*D8 
highlighted how the treatment of maternal depression 
signiﬁ cantly improves the mental health outcomes of 
school-aged oﬀ spring. Patton and colleagues4 showed 
the importance of early identiﬁ cation and treatment 
for adolescent depression, as good outcomes are more 
likely if the ﬁ rst episode of adolescent depression is 
identiﬁ ed early and treated. 
Two important messages need to be emphasised. 
First, for those treating adults with a depressive 
disorder, an appreciation of the risk to any oﬀ spring 
must be acknowledged and addressed. In the study 
reported here,7 most children with depressed parents 
had symptoms of concern. The majority of depression 
is managed in primary care settings, but a proportion 
are managed in secondary care and yet family-based 
approaches supporting carers and oﬀ spring are poorly 
studied and rarely available. The treating clinician 
might experience philosophical and practical barriers 
to identifying and including the highest risk family 
members within their treatment plan, yet some 
examples of family-focused care and family-friendly 
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